The Current State of the Treatment of Kidney Cancer

May 14, 2014
James J. Hsieh, MD, PhD

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.

Clinical Pearls

James J. Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, provides an overview of the treatment of kidney cancer.

  • The treatment of kidney cancer can be divided into two categories: anti-angiogenic therapies and mTOR inhibitors.
  • Before 2007, the main treatment options were interferon and interleukin-2.
  • Many drugs have been approved since 2007, including sorafenib, axitinib, sunitinib, pazopanib, bevacizumab, temsirolimus, and everolimus.
  • About 75-80% of patients with kidney cancer have clear cell-type disease.
  • Today, no standard of care exists for rare types of kidney cancer.